Marshall Wace
UNCY icon

Marshall Wace’s Unicycive Therapeutics UNCY Stock Holding History

Marshall Wace’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.57M Buy
547,862
+392,924
+254% +$2.9M ﹤0.01% 1716
2026
Q1 		$1.02M Buy
+154,938
New +$1.02M ﹤0.01% 2122

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Marshall Wace's UNCY Position: Q2 2026 in Review

Marshall Wace increased its Unicycive Therapeutics (UNCY) stake by 254% in Q2 2026, buying an estimated $2.9M and bringing the position to 547,862 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1716.

Marshall Wace first reported a position in UNCY in Q1 2026 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Marshall Wace held 547,862 shares of Unicycive Therapeutics worth $2.57M as of Q2 2026.
  • Marshall Wace bought 392,924 Unicycive Therapeutics shares in Q2 2026, an estimated $2.9M.
  • Unicycive Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1716 holding.
  • Marshall Wace first reported a position in Unicycive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.